BIO-TECHNE Corp 4

CFO James Hippel was granted 22,438 restricted stock units and 36,459 performance restricted stock units of Bio-Techne Corporation common stock as equity compensation on August 17, 2026.

On August 17, 2026, Bio-Techne Corporation CFO James Hippel received new equity awards consisting of 22,438 time-based restricted stock units and 36,459 performance-based restricted stock units, each RSU representing a contingent right to receive one share of common stock. These awards are in addition to his existing holdings of common stock, vested and unvested stock options with various exercise prices and expirations, and multiple prior tranches of performance and time-based restricted stock units with staggered vesting schedules through 2035. No open-market purchases or sales of common stock occurred; the Form 4 reflects routine compensation-related grants that increase Hippel’s potential equity exposure to the company subject to time- and performance-vesting conditions.

Filing Facts

CIK

842023

Ticker

TECH

Form

4

Source Type

fda

Accession

0000914190-26-000132

Alert Tier

5